Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2021 Dec 2;172(2):250–253. doi: 10.1007/s10517-021-05371-5

Secretome of Mesenchymal Bone Marrow Stem Cells: Is It Immunosuppressive or Proinflammatory?

M V Kiselevskii 1,✉, R Ya Vlasenko 1, N G Stepanyan 1, I Zh Shubina 1, S M Sitdikova 1, K I Kirgizov 1, S R Varfolomeeva 1
PMCID: PMC8636784  PMID: 34855084

Abstract

Mesenchymal stem cells (MSC) are characterized by tolerogenic potential and therefore, are used in the treatment of autoimmune diseases such as graft-versus-host disease (GVHD) reactions after allogeneic hematopoietic cell transplantation to improve the transplant functions, as well as for the therapy and prevention of cytokine storm in COVID-19 patients and some other conditions. However, MSC can exhibit proinflammatory activity, which causes risks for their clinical use. We studied the cytokine profile of bone marrow MSC culture and demonstrate intensive production of IL-6, IL-8, and chemokine MCP-1, which participate in the pathogenesis of cytokine storm and GVHD. At the same time, no anti-inflammatory IL-4 and IL-10 were detected. To reduce the risks of MSC application in the GVHD therapeutic protocols, further studies of the conditions promoting generation of MSC with tolerogenic potential and approved clinical standards of MSC use are required.

Key Words: mesenchymal stem cells, cytokines, graft-versus-host disease, hematopoietic stem cell transplantation

Footnotes

Translated from Kletochnye Tekhnologii v Biologii i Meditsine, No. 3, pp. 171-175, September, 2021

References

  • 1.Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell. 2013;13(4):392–402. doi: 10.1016/j.stem.2013.09.006. [DOI] [PubMed] [Google Scholar]
  • 2.Chan CK, Wu KH, Lee YS, Hwang SM, Lee MS, Liao SK, Cheng EH, See LC, Tsai CN, Kuo ML, Huang JL. The comparison of interleukin 6-associated immunosuppressive effects of human ESCs, fetal-type MSC, and adult-type MSC. Transplantation. 2012;94(2):132–138. doi: 10.1097/TP.0b013e31825940a4. [DOI] [PubMed] [Google Scholar]
  • 3.Clinical Commissioning Policy: Treatments for Graft versus Host Disease (GvHD) following Haematopoietic Stem Cell Transplantation. 31 March 2017. URL: https://www.england.nhs.uk/wp-content/uploads/2017/03/gvhd-heamatopoieticstem- cell.pdf
  • 4.Connard SS, Linardi RL, Even KM, Berglund AK, Schnabel LV, Ortved KF. Effects of continuous passage on the immunomodulatory properties of equine bone marrow-derived mesenchymal stem cells in vitro. Vet. Immunol. Immunopathol. 2021;234:110203. doi: 10.1016/j.vetimm.2021.110203. [DOI] [PubMed] [Google Scholar]
  • 5.Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Dj P, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315–317. doi: 10.1080/14653240600855905. [DOI] [PubMed] [Google Scholar]
  • 6.Drobyski WR, Pasquini M, Kovatovic K, Palmer J, Douglas Rizzo J, Saad A, Saber W, Hari P. Tocilizumab for the treatment of steroid refractory graft-versus-host disease. Biol. Blood Marrow Transplant. 2011;17(12):1862–1868. doi: 10.1016/j.bbmt.2011.07.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Ferrà C, de Sanjosé S, Gallardo D, Berlanga JJ, Rueda F, Marìn D, de la Banda E, Ancìn I, Peris J, Garcìa J, Grañena A. IL-6 and IL-8 levels in plasma during hematopoietic progenitor transplantation. Haematologica. 1998;83(12):1082–1087. [PubMed] [Google Scholar]
  • 8.Gazdic M, Volarevic V, Arsenijevic N, Stojkovic M. Mesenchymal stem cells: a friend or foe in immune-mediated diseases. Stem Cell Rev. Rep. 2015;11(2):280–287. doi: 10.1007/s12015-014-9583-3. [DOI] [PubMed] [Google Scholar]
  • 9.Gu L, Tseng S, Horner RM, Tam C, Loda M, Rollins BJ. Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature. 2000;404:407–411. doi: 10.1038/35006097. [DOI] [PubMed] [Google Scholar]
  • 10.Kiselevskiy M, Shubina I, Chikileva I, Sitdikova S, Samoylenko I, Anisimova N, Kirgizov K, Suleimanova A, Gorbunova T, Varfolomeeva S. Immune pathogenesis of COVID-19 intoxication: storm or silence? Pharmaceuticals (Basel). 2020;13(8):166. doi: 10.3390/ph13080166. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Kiselevskiy M, Vlasenko R, Reshetnikova V, Chikileva I, Shubina I, Osmanov E, Valiev T, Sidorova N, Batmanova N, Stepanyan N, Kirgizov K, Varfolomeeva S. Potential use of mesenchymal multipotent cells for hemopoietic stem cell transplantation: pro and contra. J. Pediatr. Hematol. Oncol. 2021;43(3):90–94. doi: 10.1097/MPH.0000000000002065. [DOI] [PubMed] [Google Scholar]
  • 12.Kyurkchiev D, Bochev I, Ivanova-Todorova E, Mourdjeva M, Oreshkova T, Belemezova K, Kyurkchiev S. Secretion of immunoregulatory cytokines by mesenchymal stem cells. World J. Stem Cells. 2014;6(5):552–570. doi: 10.4252/wjsc.v6.i5.552. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Le Blanc K, Ringdén O. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 2005;11(5):321–334. doi: 10.1016/j.bbmt.2005.01.005. [DOI] [PubMed] [Google Scholar]
  • 14.Li T, Luo C, Zhang J, Wei L, Sun W, Xie Q, Liu Y, Zhao Y, Xu S, Wang L. Efficacy and safety of mesenchymal stem cells co-infusion in allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis. Stem Cell Res Ther. 2021;12(1):246. doi: 10.1186/s13287-021-02304-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Ma S, Xie N, Li W, Yuan B, Shi Y, Wang Y. Immunobiology of mesenchymal stem cells. Cell Death Differ. 2014;21(2):216–225. doi: 10.1038/cdd.2013.158. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Martin PJ, Uberti JP, Soiffer RJ, Klingemann H, Waller EK, Daly AS, Herrmann RP, Kebriaei P. Prochymal improves response rates in patients with steroid-refractory acute graft versus host disease (SR-GVHD) involving the liver and gut: results of a randomized, placebo-controlled, multicenter phase III trial in GVHD. Biol. Blood Marrow Transplant. 2010;16(2):S169–170. doi: 10.1016/j.bbmt.2009.12.057. [DOI] [Google Scholar]
  • 17.McElvaney OJ, Curley GF, Rose-John S, McElvaney NG. Interleukin-6: obstacles to targeting a complex cytokine in critical illness. Lancet Respir. Med. 2021;9(6):643–654. doi: 10.1016/S2213-2600(21)00103-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Pricola KL, Kuhn NZ, Haleem-Smith H, Song Y, Tuan RS. Interleukin-6 maintains bone marrow-derived mesenchymal stem cell stemness by an ERK1/2-dependent mechanism. J. Cell. Biochem. 2009;108(3):577–588. doi: 10.1002/jcb.22289. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Siegel G, Schäfer R, Dazzi F. The immunosuppressive properties of mesenchymal stem cells. Transplantation. 2009;87(9, Suppl):S45-S49. doi: 10.1097/TP.0b013e3181a285b0 [DOI] [PubMed]
  • 20.Steensberg A, Fischer CP, Keller C, Møller K, Pedersen BK. IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans. Am. J. Physiol. Endocrinol. Metab. 2003;285(2):E433–E437. doi: 10.1152/ajpendo.00074.2003. [DOI] [PubMed] [Google Scholar]
  • 21.Szabolcs P, Visani G, Locatelli F, Kleiner G, Talano J, Nemecek E, Kurtzberg J. Treatment of steroid-refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; Results of the pediatric subset in a phase III randomized, placebo-controlled study. Biol. Blood Marrow Transplant. 2010;16(2):S298. doi: 10.1016/j.bbmt.2009.12.426. [DOI] [Google Scholar]
  • 22.Wu X, Chen L, Xu Y, Wen J, Ruan Y, He Y, Li C. The relationship between some cytokines and graft versus host disease after allogeneic hematopoietic stem cell transplantation in thalassemia major patients. Blood. 2015;126(23):5471. doi: 10.1182/blood.V126.23.5471.5471. [DOI] [Google Scholar]
  • 23.Zumla A, Wang FS, Ippolito G, Petrosillo N, Agrati C, Azhar EI, Chang C, El-Kafrawy SA, Osman M, Zitvogel L, Galle PR, Locatelli F, Gorman E, Cordon-Cardo C, O’Kane C, McAuley D, Maeurer M. Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy — Achieving global consensus and visibility for cellular hostdirected therapies. Int. J. Infect. Dis. 2020;96:431–439. doi: 10.1016/j.ijid.2020.05.040. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Bulletin of Experimental Biology and Medicine are provided here courtesy of Nature Publishing Group

RESOURCES